Sthanu Subramanian: Dabigatran and Mechanical Heart Valves
Sthanu Subramanian, Pediatrician, shared a post on X about a recent article by Noel C. Chan et al. published in Arteriosclerosis, Thrombosis, and Vascular Biology, adding:
“Dabigatran and Mechanical heart valves.
Dabigatran (Pradaxa) is contraindicated for mechanical heart valves because it is significantly less effective at preventing blood clots on artificial valves and carries a higher risk of major bleeding compared to traditional treatments like Warfarin.
The danger of using dabigatran in these patients was proven by the RE-ALIGN Trial, which was stopped early due to severe safety risks.
The specific reasons for this include:
1. Higher Rates of Valve Thrombosis:
Dabigatran only targets one specific clotting factor (thrombin).
Mechanical valves are highly prone to clot formation, and warfarin’s broader mechanism of action is much more effective at preventing clots from building up on the artificial material.
2. Increased Risk of Strokes:
Because dabigatran fails to adequately prevent clots from forming on the valves, users experienced more strokes and systemic embolisms.
3. Excessive Bleeding:
The drug also led to a significantly higher rate of major bleeding events, including dangerous bleeding in the pericardial space surrounding the heart.
4. Absorption Issues:
Dabigatran has very low oral bioavailability and can cause topical anticoagulant effects in the gastrointestinal tract, contributing to higher bleeding risks.
Mechanisms of mechanical heart valve thrombosis and the differential effects of anticoagulants on thrombin generation.”
Title: Anticoagulation for Mechanical Heart Valves: Will Oral Factor Xa Inhibitors Be Effective?
Authors: Noel C. Chan, Jeffrey I. Weitz, John W. Eikelboom

Other posts featuring Sthanu Subramanian on Hemostasis Today.
-
Nov 17, 2026, 10:41Elena Petkovic։ Highlights from the ISBT–WHO Plasma Management Workshop
-
Nov 17, 2026, 10:30Cheng-Hock Toh: Haematology Is Everywhere – But Is It Recognised?
-
Nov 17, 2026, 10:23Akshat Jain: The Importance of Knowing Your Sickle Cell Status
-
Nov 17, 2026, 10:12Caitlin Raymond: What Does Apheresis Really Cost?
-
Nov 17, 2026, 05:47Multidisciplinary Teams Kick Off SAHF MASAC ES 2026 with Pre-Symposium Workshops – South African Haemophilia Foundation
-
Nov 17, 2026, 05:41Boitumelo Malatji: South African Delegation Advances Advocacy Strategies at NNHF Southern Africa Workshop
-
Nov 17, 2026, 05:36Joining the PACTA Uganda Mental Health and Addiction Community Camp 2026 – Tackle Sickle Cell Africa
-
Nov 17, 2026, 05:30Nathan Connell: Women’s Hematology Summit 2027 to Address Hematologic Health Across the Lifespan
-
Nov 17, 2026, 05:25Mane Kurghinyan: Representing Armenia and HemAI Dynamics at the Falling Walls Lab Global Finale 2026